GlassScriptPhysician profile
Revital Ahl
NPI 1538769062
$1,777.10
in general payments reported to CMS, 2019-2025
23 companies · $49.04 in 2025
The $49.04 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $151 · 2022: $688 · 2023: $823 · 2024: $66.50 · 2025: $49.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $938.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $355.36 | 2021-2024 | Repatha, Evenity, Prolia |
| Glaxosmithkline, LLC. | $234.25 | 2022-2023 | Trelegy Ellipta |
| Amarin Pharma, INC. | $179.25 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $139.03 | 2021-2023 | Dupixent |
| Janssen Pharmaceuticals, INC | $125.79 | 2022-2023 | Xarelto |
| Edwards Lifesciences Corporation | $104.26 | 2022-2025 | Sapien 3 Ultra Resilia |
| Alnylam Pharmaceuticals INC. | $83.23 | 2022-2023 | Onpattro |
| Daiichi Sankyo INC. | $75.17 | 2022-2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $71.65 | 2021 | |
| Ironwood Pharmaceuticals, INC | $62.89 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.48 | 2022 | |
| Radius Health, INC. | $48.02 | 2023 | Tymlos |
| Azurity Pharmaceuticals, INC. | $37.66 | 2023 | Adthyza, Horizant |
| Biohaven Pharmaceutical Holding Company LTD. | $30.08 | 2022 | |
| Esperion Therapeutics, INC. | $25.56 | 2023 | Nexletol |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $24.59 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $23.47 | 2023 | Camzyos |
| Takeda Pharmaceuticals U.S.A., INC. | $21.32 | 2023 | Trintellix |
| Novo Nordisk INC | $20.28 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.27 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.38 | 2023 | Xifaxan |
| Ibsa Pharma INC. | $14.28 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Revital Ahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.